Study of Regorafenib in Patients With Advanced Myeloid Malignancies
Status:
Active, not recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This research study is studying a drug as a possible treatment for advanced myeloid
malignancies including AML (acute myeloid leukemia), MDS (myelodysplastic syndrome) and MPN
(myeloproliferative neoplasms)
The intervention involved in this study is:
-Regorafenib (Stivarga)